EGFR-TKI drug-resistant lung cancer survival is over 5 years?IIIA's new auxiliary therapy and synchronous chemotherapy+immunity How to choose from stage IIIA?Jinling Lung Cancer Network Forum was here on July 26!

*For medical professionals for reading reference

Seeing immunotherapy brings new vitality to patients with lung cancer!

How to formulate a standardized treatment plan after lung cancer EGFR-TKI treatments? Can immunotherapy bring the hope of survival to patients after targeted therapy? Immunotherapy -related carditis has a low incidence and high disease mortality. How should we predict and deal with it? IIIA's new auxiliary treatment of lung squamous carcinoma or synchronous chemotherapy+immunotherapy? Immunotherapy related adverse reactions (IRAE) related to efficacy?

Review

Professor Jiang Wenrui, the Department of Respiratory and Critical Medicine of the University of Air Force Medical University, shared the diagnosis and treatment of patients with EGFR L858R+ IA3 stage of the elderly. What should be treated after treatment? Should choose observation or auxiliary treatment after surgery? Two mixed glass density nodules (MGGN) should choose surgery, ablation or targeted therapy? What should I choose individualized?

Dr. Wei Yuqing, the Department of Respiratory and Critical Medicine of the First Affiliated Hospital of Wannan Medical College, shared the treatment of patients with IVB pulmonary adenocarcinoma in stage of IVB. Patients received 4 cycles of immune combined chemotherapy. The efficacy was evaluated as PR. For SD. How should immune -related pneumonia (CIP) be differentiated to diagnose? What is the correlation between glucocorticoid application and immunotherapy?

Dr. Wang Bing, a department of chest oncology at Hangzhou Cancer Hospital affiliated to Zhejiang University School of Medicine, shared the clinical management and practice of advanced lung cancer in advanced period. Patient diagnosis is Phase IIIA right pulmonary adenocarcinoma, synchronous chemotherapy, surgical therapy, and neo -assisted treatment? After synchronizing the chemotherapy, PR is reached, and II degrees pneumonia occurs after the treatment optional. In the 8 -cycle of immunotherapy, lymph nodes and brain metastases occur. Should the second -line treatment choose to continue immunotherapy?

Hot spots in this issue

Professor Leng Zaijun of the First Affiliated Hospital of China University of Science and Technology brings a case of lung cancer specifications that survive for more than 5 years. EGFR-TKI has become a first-line standard treatment plan for driving gene-positive non-small cell lung cancer (NSCLC), but many patients in the treatment process will have drug resistance. The patient's progress (PD) after the treatment of Gibitinib (PD), switched to three generations of EGFR-TKI Oshitinib for treatment again, and a brain metastases. How should the next step formulate a treatment strategy? Can chemotherapy+Bevarzumab benefit? Is the potential beneficiary of patients immunotherapy? What treatment plan makes patients exceed 60 months after repeated progress?

Dr. Wang Bing of the First Affiliated Hospital of the Army Military Medical University brought a case of small -cell lung cancer related to immunotherapy related to ECG. The patient's first and second lines use chemotherapy. Although it is partially relieved (PR) after treatment, PD still occurs. Unexpectedly, the driving gene mutations were obtained, and the PD-L1 expression level was high, and immunotherapy was used. For more than July after immunotherapy, patients have myocarditis. What should I do at this time? Immunotherapy -related carditis has a low incidence and high mortality. Is there any related risk factors predictable? How to find it early?

Professor Wang Xiaofei from Ruijin Hospital affiliated to Shanghai Jiaotong University brought a case of phase IIIA cancer cases for immunochemical combined chemotherapy. After consultation with MDT, the patient considers the white protein paclitaxel+card platinum+Paborizumab newly adjusted therapy, and then seriously immune -related skin adverse reactions occur. What should I do for immune -related skin adverse reactions? After the new auxiliary therapy was over, the lobe cutting was removed with lymph nodes, and the postoperative evaluation was fully relieved (PCR). IIIA's new auxiliary treatment and synchronous chemotherapy+immunotherapy after the treatment of lung squamous cancer, which solution can obtain greater OS benefits? Immunotherapy -related adverse reactions are closely related to curative effect?

The first release of this article: the medical world tumor channel

Author of this article: Cat on the window sill

Editor in charge: Sweet

- END -